Structure-guided development of dual β2 adrenergic/dopamine D2 receptor agonists

Area of Science:

• Medicinal Chemistry
• Neuropharmacology
• Structural Biology

Background:

• G protein-coupled receptors (GPCRs) are crucial drug targets.
• Developing ligands that modulate multiple GPCRs offers therapeutic advantages.
• Dual-acting ligands for beta-2 adrenergic and dopamine D2 receptors are of interest for neurological conditions.

Purpose of the Study:

• To design and synthesize novel dual-acting ligands targeting beta-2 adrenergic and dopamine D2 receptors.
• To explore structure-activity relationships for GPCR agonists with dual activity.
• To identify molecular probes with tuned dual receptor modulation.

Main Methods:

• Structure-guided drug design based on GPCR crystal structures.
• Chemical synthesis of benzoxazinone derivatives.
• In vitro biological assays to assess receptor binding and activation (agonist/antagonist properties).

Main Results:

• Identification of benzoxazinone (R)-3 as a beta-2 adrenergic receptor agonist and dopamine D2 receptor agonist.
• Characterization of desOH-3 as a beta-2 adrenergic receptor antagonist and dopamine D2 receptor agonist with low nanomolar affinity.
• Demonstration of tuned dual activity in the synthesized compounds.

Conclusions:

• The structure-guided approach successfully yielded potent dual-acting GPCR ligands.
• The identified compounds serve as valuable molecular probes for further research.
• These compounds represent a promising starting point for developing treatments for neurological disorders.